This is what I’d do about GlaxoSmithKline’s big 5% dividend yield right now

Find out whether GlaxoSmithKline plc (LON: GSK) makes it into my dividend portfolio.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve lost count of how many shares I’ve rejected for my long-term income portfolio, but it’s a lot! It doesn’t matter whether they were small-caps, mid-caps or great big well-known FTSE 100 companies, they’ve all gone the same way – out the window as far as I’m concerned.

Of course, I’ve considered them in the first place because they’ve all had a large dividend yield, or perhaps an average yield but with a dividend that has been growing at an impressive annual rate. But, for me, big and growing yields are not enough on their own. I want ‘quality’ dividends, which means they must be sustainable.

The search for quality

I skip most cyclical firms. The trouble with cyclicals, as I see it, is that they often go in disguise as big-dividend-payers, but they fail the test of sustainability. Look at the fat yields available from companies such as housebuilder Persimmon, banker Lloyds Banking Group and miner Rio Tinto. At first glance, those firms look tempting for an income portfolio with their big payouts and low valuations.

But I think cyclical firms with low valuations following a period of strong profits are dangerous.  In the next cyclical down-leg, they can be vulnerable to the collapse of their profits, share prices and dividends. In other words, they look their most attractive when they are at their most dangerous. What’s the point of collecting the dividend now when there’s a risk that a share price plunge down the road could wipe out my income gains?

Dividends can also be at risk because of weak business models. I reckon it’s important that a big or growing dividend is backed up with an underlying business that scores well against quality indicators, which would suggest that the company is trading in a strong and profitable niche of the market.

Quality and forward-looking opportunity

One company that I’m happy to add to my income portfolio is pharmaceutical giant GlaxoSmithKline (LSE: GSK). The dividend yield runs just above 5%, which looks attractive, although I admit it’s not perfect because the dividend has been flat for a few years and I’d prefer to see the payment rising a little annually.

Nevertheless, the company operates in a defensive sector and I see defensive businesses as operating at the opposite end of the scale from cyclical businesses. Whereas the cyclicals tend to see their profits rise and fall along with the undulations of the wider economy, defensives tend to enjoy stable incoming cash flow and profits because of evergreen demand for their products and services. As such, a defensive business is often well placed to support its dividend payments over the long haul. I think the pharmaceutical sector is fertile ground for finding decent dividend-paying firms, because customers tend to keep buying medicines whatever the general economic weather.

Indeed, GlaxoSmithKline has a stable record of incoming cash flow that supports profits and the dividend payment. There’s also a good showing on quality indicators such as the return on capital and the operating margin. Looking forward, recent news of the firm’s plans to combine its consumer health businesses with that of Pfizer in a new joint venture could unlock value. Overall, I see the shares as attractive and would be happy to add them to my income portfolio today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »